Monthly Extracts – October 2020

 November 3, 2020 – 8 min read 

 Author: Dave Neundorfer 

Over the past few months, we’ve shared our perspective on what the cannabinoid industry needs to graduate from a nascent, $1B industry into the mainstream, cross-category, $20B+ powerhouse that analysts have heralded since the passing of the 2018 farm bill. This shift is happening now, driven by research, innovation, and a flight to quality by forward-thinking brands and the CPG “buyers of tomorrow.” 

At OBX, most of our research and innovation has been focused on minor cannabinoid production and formulation and downstream technological advancements that make those ingredients and formulations more effective and palatable to the mainstream consumer. 

Minor Cannabinoid Production and Formulation: We’ve blogged about the therapeutic potential of CBN, CBDV, THCV, & CBC, which are already playing a critical role in delivering function-specific formulations that the market demands. Working with minor cannabinoids demands production, testing, and product development rigor and precision, an all-hands on deck pursuit between partners like LYGOS, our in-house ops and quality assurance teams, and our 3rd-party control laboratory. 

Technological Advancements: We’ve partnered with other high-integrity organizations like Prinova and Volunteer Botanicals to fuel our ingredient innovation pipeline for our current clients and the buyers of tomorrow. Prinova is our nano-emulsification partner that can convert any of our cannabinoids into water soluble powder or liquid, whereas Volunteer Botanical can convert cannabinoids into a standardized, flowable powder that can be used for precisely dosed dissolvable tabs or capsules. Both of these innovation partners help streamline the adoption of cannabinoids into the routines of mainstream consumers. 

Over the past few months, we’ve shared our perspective on what the cannabinoid industry needs to graduate from a nascent, $1B industry into the mainstream, cross-category, $20B+ powerhouse that analysts have heralded since the passing of the 2018 farm bill. This shift is happening now, driven by research, innovation, and a flight to quality by forward-thinking brands and the CPG “buyers of tomorrow.” 

At OBX, most of our research and innovation has been focused on minor cannabinoid production and formulation and downstream technological advancements that make those ingredients and formulations more effective and palatable to the mainstream consumer. 

Minor Cannabinoid Production and Formulation: We’ve blogged about the therapeutic potential of CBN, CBDV, THCV, & CBC, which are already playing a critical role in delivering function-specific formulations that the market demands. Working with minor cannabinoids demands production, testing, and product development rigor and precision, an all-hands on deck pursuit between partners like LYGOS, our in-house ops and quality assurance teams, and our 3rd-party control laboratory. 

Technological Advancements: We’ve partnered with other high-integrity organizations like Prinova and Volunteer Botanicals to fuel our ingredient innovation pipeline for our current clients and the buyers of tomorrow. Prinova is our nano-emulsification partner that can convert any of our cannabinoids into water soluble powder or liquid, whereas Volunteer Botanical can convert cannabinoids into a standardized, flowable powder that can be used for precisely dosed dissolvable tabs or capsules. Both of these innovation partners help streamline the adoption of cannabinoids into the routines of mainstream consumers. 

New York tries to restore order to CBD market, clears way for hemp-infused drinks

Read More

Turning Point Brands Backs Cannabinoid Company Dosist With $15M

Read More

CBN Isolate

10N Distillate

CBDV Isolate